Results 11 to 20 of about 25,780 (241)

The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation

Health Technology Assessment, 2010
Objectives: To assess the clinical effectiveness and cost-effectiveness of topotecan as second-line treatment for small cell lung cancer (SCLC). Data sources: Bibliographic databases were searched from 1990 to February 2009, including the Cochrane ...
E Loveman, J Jones, D Hartwell, A Bird, P Harris, K Welch, A Clegg   +6 more
doaj   +2 more sources

Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study [PDF]

Gynecologic Oncology, 2023
Objective. To determine whether a non-platinum chemotherapy doublet improves overall survival (OS) among patients with recurrent/metastatic cervical carcinoma. Methods.
K. Tewari, M. Sill, M. Birrer, R. Penson, Helen Q. Huang, D. Moore, L. Ramondetta, L. Landrum, A. Oaknin, T. Reid, M. Leitao, Helen E. Michael, B. Monk   +12 more
semanticscholar   +2 more sources

Is Intravenous and Oral Topotecan in Small-Cell Lung Cancer Truly Equal? A Case Report [PDF]

Case Reports in Oncology
Introduction: Treatment with topotecan is standard-of-care therapy for relapsed small-cell lung cancer (SCLC). Both oral and intravenous administrations of topotecan have been extensively researched and are found to be equally effective with less adverse
Davien Deraedt, Saartje Verfaillie, Jokke Wynants, Kristof Cuppens   +3 more
doaj   +2 more sources

Triggering of Suicidal Erythrocyte Death by Topotecan [PDF]

Cellular Physiology and Biochemistry, 2015
Background/Aims: The topoisomerase I inhibitor topotecan is used as treatment of various malignancies. The substance is effective by triggering tumor cell apoptosis. In analogy to apoptosis of nucleated cells, erythrocytes may enter eryptosis, a suicidal
Rosi Bissinger, Ghada Bouguerra, Katja Stockinger, Salem Abbès, Florian Lang   +4 more
doaj   +2 more sources

Therapeutic uses of topotecan for thoracic malignancies

Oncology Reviews, 2011
Topotecan, a topoisomerase 1 inhibitor (topo1-i), is a semi-synthetic derivative of camptothecan with wellestablished cytotoxic properties. It is licensed for the treatment of relapsed, sensitive small cell lung cancer (SCLC) and for second line ...
Saoirse O. Dolly, Craig P. Carden, James S. Myerson, Martina Puglisi, Mary E. O’Brien   +4 more
doaj   +2 more sources

Inhibition of Poly(ADP-Ribose) polymerase enhances the toxicity of 131I-Metaiodobenzylguanidine/Topotecan combination therapy to cells and xenografts that express the noradrenaline transporter [PDF]

, 2012
Targeted radiotherapy using [131I]meta-iodobenzylguanidine ([131I]MIBG) has produced remissions in some neuroblastoma patients. We previously reported that combining [131I]MIBG with the topoisomerase I (Topo-I) inhibitor topotecan induced long-term DNA ...
McCluskey, Anthony G, Babich, John W, Champion, Sue, Mairs, Robert J, Boyd, Marie, Gaze, Mark N, Tesson, Mathias, Pimlott, Sally L   +7 more
core   +4 more sources

Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-center, phase 1b trial

The Lancet Oncology, 2022
SUMMARY Background: Topotecan is cytotoxic to glioma cells but clinically ineffective due to drug delivery limitations. Systemic delivery is limited by toxicity and insufficient brain penetrance while convection-enhanced delivery has been restricted to a
Eleonora F. Spinazzi, Michael G. Argenziano, Pavan S. Upadhyayula, M. Banu, J. Neira, Dominique M. O. Higgins, Peter B. Wu, Brianna Pereira, Aayushi Mahajan, N. Humala, Osama Al-Dalahmah, Wen-Ting Zhao, A. Save, B. Gill, D. Boyett, Tamara Marie, J. Furnari, Tejaswi D. Sudhakar, S. Stopka, Michael S. Regan, Vanessa V. Catania, Laura Good, S. Zacharoulis, M. Behl, P.D. Petridis, S. Jambawalikar, A. Mintz, A. Lignelli, N. Agar, P. Sims, M. Welch, A. Lassman, F. Iwamoto, Randy S. D'Amico, J. Grinband, P. Canoll, J. Bruce   +36 more
semanticscholar   +1 more source

Transformation to Small-Cell Lung Carcinoma and Then to Sarcomatoid Carcinoma in an EGFR-Mutant Lung Adenocarcinoma Patient During Systemic Therapy: A Case Report. [PDF]

Thorac Cancer
An EGFR‐mutant lung adenocarcinoma underwent sequential histological transformations to combined small‐cell carcinoma and sarcomatoid carcinoma during systemic therapy. Serial re‐biopsy demonstrated dynamic tumor evolution and molecular alterations associated with treatment resistance.
Huang B, Lu T, Hong R, Liu X, Gao X, Xu Y, Chen M, Zhong W, Wang M, Zhao J.   +9 more
europepmc   +2 more sources

Ocular and systemic toxicity of high-dose intravitreal topotecan in rabbits: implications for retinoblastoma treatment

Experimental Eye Research, 2022
Although many more eyes of children with retinoblastoma are salvaged now compared to just 10 years ago, the control of vitreous seeding remains a challenge.
M. D. Del Sole, M. Clausse, P. Nejamkin, Brais Cancela, M. Del Río, G. Lamas, F. Lubieniecki, J. Francis, D. Abramson, G. Chantada, P. Schaiquevich   +10 more
semanticscholar   +1 more source

DNA repair and cholesterol-mediated drug efflux induce dose-dependent chemoresistance in nutrient-deprived neuroblastoma cells

iScience, 2021
Summary: Neuroblastoma is a solid, heterogeneous pediatric tumor. Chemotherapy is widely used to treat neuroblastoma. However, dose-dependent responses and chemoresistance mechanisms of neuroblastoma cells to anticancer drugs remain challenging. Here, we
Soo Yeon Chae, Dowoon Nam, Do Young Hyeon, Areum Hong, Timothy Dain Lee, Sujin Kim, Dongjoon Im, Jiwon Hong, Chaewon Kang, Ji Won Lee, Daehee Hwang, Sang-Won Lee, Hugh I. Kim   +12 more
doaj   +1 more source